143 related articles for article (PubMed ID: 36835014)
21. Inhibiting tumor growth of colorectal cancer by blocking the expression of vascular endothelial growth factor receptor 3 using interference vector-based RNA interference.
Lui Z; Ma Q; Wang X; Zhang Y
Int J Mol Med; 2010 Jan; 25(1):59-64. PubMed ID: 19956902
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells.
Kim S; You D; Jeong Y; Yoon SY; Kim SA; Lee JE
Eur J Pharmacol; 2021 Mar; 895():173868. PubMed ID: 33460613
[TBL] [Abstract][Full Text] [Related]
23. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
Byerly JH; Port ER; Irie HY
Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
[TBL] [Abstract][Full Text] [Related]
24. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
Santana-Krímskaya SE; Franco-Molina MA; Zárate-Triviño DG; Prado-García H; Zapata-Benavides P; Torres-Del-Muro F; Rodríguez-Padilla C
Biomed Pharmacother; 2020 Jun; 126():110062. PubMed ID: 32172064
[TBL] [Abstract][Full Text] [Related]
25. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
[TBL] [Abstract][Full Text] [Related]
26. Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3.
Hsu MC; Pan MR; Hung WC
Cells; 2019 Mar; 8(3):. PubMed ID: 30901976
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
Gründker C; Wokoun U; Hellriegel M; Emons G
J Obstet Gynaecol Res; 2019 Jul; 45(7):1334-1342. PubMed ID: 31016845
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck.
Neuchrist C; Erovic BM; Handisurya A; Fischer MB; Steiner GE; Hollemann D; Gedlicka C; Saaristo A; Burian M
Head Neck; 2003 Jun; 25(6):464-74. PubMed ID: 12784238
[TBL] [Abstract][Full Text] [Related]
29. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study.
Goh W; Sleptsova-Freidrich I; Petrovic N
J Pharm Pharm Sci; 2014; 17(3):439-46. PubMed ID: 25224353
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of anethole and doxorubicin alleviates cell proliferation, cell cycle arrest, and ER stress and promotes ROS-mediated apoptosis in triple-negative breast cancer cells.
Arumugam P; Sampathkumar B; Perumalsamy H; Balusamy SR; Ramesh V; Sundaravadevel S
J Biochem Mol Toxicol; 2021 Dec; 35(12):e22928. PubMed ID: 34585488
[TBL] [Abstract][Full Text] [Related]
31. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
32. New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin.
Ciocan-Cȃrtiţă CA; Jurj A; Raduly L; Cojocneanu R; Moldovan A; Pileczki V; Pop LA; Budişan L; Braicu C; Korban SS; Berindan-Neagoe I
Mol Cell Biochem; 2020 Dec; 475(1-2):285-299. PubMed ID: 32888160
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
[TBL] [Abstract][Full Text] [Related]
34. Macrophage-Induced Lymphangiogenesis and Metastasis following Paclitaxel Chemotherapy Is Regulated by VEGFR3.
Alishekevitz D; Gingis-Velitski S; Kaidar-Person O; Gutter-Kapon L; Scherer SD; Raviv Z; Merquiol E; Ben-Nun Y; Miller V; Rachman-Tzemah C; Timaner M; Mumblat Y; Ilan N; Loven D; Hershkovitz D; Satchi-Fainaro R; Blum G; Sleeman JP; Vlodavsky I; Shaked Y
Cell Rep; 2016 Oct; 17(5):1344-1356. PubMed ID: 27783948
[TBL] [Abstract][Full Text] [Related]
35. Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells.
Yamashita N; Kanno Y; Saito N; Terai K; Sanada N; Kizu R; Hiruta N; Park Y; Bujo H; Nemoto K
Biochem Biophys Res Commun; 2019 Aug; 516(3):693-698. PubMed ID: 31253396
[TBL] [Abstract][Full Text] [Related]
36. SMAGP regulates doxorubicin sensitivity in triple-negative breast cancer cells via modulating mitochondrial respiration.
Xiao H; Yang X; Huang S
Cancer Chemother Pharmacol; 2023 Jan; 91(1):43-52. PubMed ID: 36436062
[TBL] [Abstract][Full Text] [Related]
37. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin-paclitaxel sequential treatment: insights of DNA methylation and gene expression changes of luminal A and triple negative breast cancer cell lines.
Hamadneh L; Abu-Irmaileh B; Al-Majawleh M; Bustanji Y; Jarrar Y; Al-Qirim T
Mol Cell Biochem; 2021 Oct; 476(10):3647-3654. PubMed ID: 34050450
[TBL] [Abstract][Full Text] [Related]
39. EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models.
Giró-Perafita A; Rabionet M; Planas M; Feliu L; Ciurana J; Ruiz-Martínez S; Puig T
Molecules; 2019 Mar; 24(6):. PubMed ID: 30875891
[TBL] [Abstract][Full Text] [Related]
40. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
